Marino Stram & Associates’s DexCom DXCM Stock Holding History

Marino Stram & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-52	Closed	-$2K	–	210
2019 Q1	$2K	Buy	52 +4	+8%	+$141	﹤0.01%	521
2018 Q4	$1K	Buy	+48	New	+$1.52K	﹤0.01%	549

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marino Stram & Associates's DXCM Position: Q2 2019 in Review

Marino Stram & Associates sold out of DexCom (DXCM) in Q2 2019, closing a stake of 52 shares — an estimated $2K sold.

Marino Stram & Associates first reported a position in DXCM in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 418 funds tracked by Wall St. Rank hold DXCM as of Q2 2019.

Marino Stram & Associates reported no remaining DexCom position as of Q2 2019 after selling out during the quarter.
Marino Stram & Associates sold 52 DexCom shares in Q2 2019, an estimated $2K.
Marino Stram & Associates first reported a position in DexCom in Q4 2018 and held it in 2 quarters.
Marino Stram & Associates's DexCom position peaked at $2K in Q1 2019.
418 funds tracked by Wall St. Rank held DexCom as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.